Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9I6QG
|
|||
| Drug Name |
NE3107
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
| Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1/2 | [2] | ||
| Company |
BioVie
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04669028) A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05083260) A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107. U.S.National Institutes of Health. | |||
| REF 3 | NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design?and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021 Aug;11(4):289-298. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.